Cargando…

Editorial: Development of small molecule inhibitors and antibodies targeting AXL for tumor therapy and infectious disease control

Detalles Bibliográficos
Autores principales:	Pyo, Kyoung-Ho, Rahman, S. M. Mazidur, Boraschi, Diana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9872103/ https://www.ncbi.nlm.nih.gov/pubmed/36703780 http://dx.doi.org/10.3389/fonc.2022.1121120

Ejemplares similares

A Potent and Selective Dual Inhibitor of AXL and MERTK Possesses Both Immunomodulatory and Tumor-Targeted Activity
por: Rios-Doria, Jonathan, et al.
Publicado: (2020)

The Development of AXL Inhibitors in Lung Cancer: Recent Progress and Challenges
por: Sang, Yun Beom, et al.
Publicado: (2022)

Incorporation of SKI-G-801, a Novel AXL Inhibitor, With Anti-PD-1 Plus Chemotherapy Improves Anti-Tumor Activity and Survival by Enhancing T Cell Immunity
por: Lee, Wongeun, et al.
Publicado: (2022)

Affinity probes based on small-molecule inhibitors for tumor imaging
por: Yi, Xinzeyu, et al.
Publicado: (2022)

Targeting of the AXL receptor tyrosine kinase by small molecule inhibitor leads to AXL cell surface accumulation by impairing the ubiquitin-dependent receptor degradation
por: Lauter, Markus, et al.
Publicado: (2019)

Immune Evasion Mechanism and AXL
por: Son, Hye-Youn, et al.
Publicado: (2021)

RIPK3 and AXL Expression Study in Primary Cutaneous Melanoma Unmasks AXL as Predictor of Sentinel Node Metastasis: A Pilot Study
por: Nicolè, Lorenzo, et al.
Publicado: (2021)

AXL Overexpression in Tumor-Derived Endothelial Cells Promotes Vessel Metastasis in Patients With Hepatocellular Carcinoma
por: Chai, Zong-Tao, et al.
Publicado: (2021)

Editorial: Molecules of the extracellular matrix as cancer targets
por: Karamanos, Nikos K., et al.
Publicado: (2022)

Gas6/AXL pathway: immunological landscape and therapeutic potential
por: Zhai, Xiaoqian, et al.
Publicado: (2023)

Megakaryocytic Expansion in Gilteritinib-Treated Acute Myeloid Leukemia Patients Is Associated With AXL Inhibition
por: Suknuntha, Kran, et al.
Publicado: (2020)

AXL targeting by a specific small molecule or monoclonal antibody inhibits renal cell carcinoma progression in an orthotopic mice model
por: Chen, Tony J., et al.
Publicado: (2021)

Small-Molecule Inhibitor Targeting Protein Kinase D: A Potential Therapeutic Strategy
por: Lv, Die, et al.
Publicado: (2021)

Editorial: Discovery of small molecule lead compounds: A driving force to unravel new anticancer targets and mechanisms
por: Zhang, Yan, et al.
Publicado: (2023)

Altered expression of AXL receptor tyrosine kinase in gastrointestinal cancers: a promising therapeutic target
por: Pidkovka, Nataliya, et al.
Publicado: (2023)

Development of the phenylpyrazolo[3,4-d]pyrimidine-based, insulin-like growth factor receptor/Src/AXL-targeting small molecule kinase inhibitor
por: Lee, Ho Jin, et al.
Publicado: (2021)

Small Molecule Inhibitors in Adult High-Grade Glioma: From the Past to the Future
por: Huang, Wenda, et al.
Publicado: (2022)

Axl, Immune Checkpoint Molecules and HIF Inhibitors from the Culture Broth of Lepista luscina
por: Kotajima, Mihaya, et al.
Publicado: (2022)

Recent Advances in the Development of Non-PIKKs Targeting Small Molecule Inhibitors of DNA Double-Strand Break Repair
por: Kelm, Jeremy M., et al.
Publicado: (2022)

Giving AXL the axe: targeting AXL in human malignancy
por: Gay, Carl M, et al.
Publicado: (2017)

Editorial: Association Between Human Cancers and Small DNA Tumor Viruses
por: Tognon, Mauro
Publicado: (2020)

A dual MET/AXL small‐molecule inhibitor exerts efficacy against gastric carcinoma through killing cancer cells as well as modulating tumor microenvironment
por: Zhu, Chenjing, et al.
Publicado: (2020)

Imprime PGG Enhances Anti-Tumor Effects of Tumor-Targeting, Anti-Angiogenic, and Immune Checkpoint Inhibitor Antibodies
por: Chan, Anissa S. H., et al.
Publicado: (2022)

Targeting Tumor Microenvironment by Small-Molecule Inhibitors
por: Zhong, Shangwei, et al.
Publicado: (2019)

IDO Inhibitor and Gallic Acid Cross-Linked Small Molecule Drug Synergistic Treatment of Melanoma
por: Liu, Hongmei, et al.
Publicado: (2022)

Structure-based discovery of a novel small-molecule inhibitor of TEAD palmitoylation with anticancer activity
por: Gridnev, Artem, et al.
Publicado: (2022)

Synergism of the receptor tyrosine kinase Axl with ErbB receptors mediates resistance to regorafenib in hepatocellular carcinoma
por: Breitenecker, Kristina, et al.
Publicado: (2023)

Inhibiting receptor tyrosine kinase AXL with small molecule inhibitor BMS-777607 reduces glioblastoma growth, migration, and invasion in vitro and in vivo
por: Onken, Julia, et al.
Publicado: (2016)

Targeted p53 on Small-Molecules-Induced Ferroptosis in Cancers
por: Zhang, Weifen, et al.
Publicado: (2018)

Small Molecules Targeting HATs, HDACs, and BRDs in Cancer Therapy
por: Wu, Donglu, et al.
Publicado: (2020)

Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) Non-Small Cell Lung Cancer Globally?
por: Ou, Sai-Hong Ignatius, et al.
Publicado: (2014)

Targeting AXL in NSCLC
por: Zaman, Aubhishek, et al.
Publicado: (2021)

Editorial: Targeted cancer therapies, from small molecules to antibodies, volume II
por: Su, Chao-Yue, et al.
Publicado: (2023)

Glycoengineering of Therapeutic Antibodies with Small Molecule Inhibitors
por: Li, Shasha, et al.
Publicado: (2021)

Editorial: Novel Targets and Targeting Technologies to Modulate Tumor Microenvironment
por: Prakash, Jai, et al.
Publicado: (2016)

Editorial: Tumor Cell Metabolism and Autophagy as Therapeutic Targets
por: Jacobo-Herrera, Nadia, et al.
Publicado: (2020)

Editorial: Targeting tumor vasculature to enhance cancer immunotherapy
por: Yang, Jieying, et al.
Publicado: (2023)

A Small-Molecule Inhibitor of RAD51 Reduces Homologous Recombination and Sensitizes Multiple Myeloma Cells to Doxorubicin
por: Alagpulinsa, David A., et al.
Publicado: (2014)

Modulation of ERCC1-XPF Heterodimerization Inhibition via Structural Modification of Small Molecule Inhibitor Side-Chains
por: Weilbeer, Claudia, et al.
Publicado: (2022)

MYCN mRNA degradation and cancer suppression by a selective small-molecule inhibitor in MYCN-amplified neuroblastoma
por: Liu, Tao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_r2pmtbq4en01qh2h5615oj6l17